HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jeffrey A Ecsedy Selected Research

MLN 8237

1/2020Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
3/2017Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
12/2015Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
6/2015MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.
1/2015Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer.
9/2014Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
6/2014Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
5/2014The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
1/2014Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.
4/2013The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jeffrey A Ecsedy Research Topics

Disease

22Neoplasms (Cancer)
01/2020 - 03/2007
3Neuroblastoma
03/2017 - 02/2013
3Melanoma (Melanoma, Malignant)
06/2016 - 01/2015
2Neurofibrosarcoma (MPNST)
03/2017 - 09/2012
2Hematologic Neoplasms (Hematological Malignancy)
06/2015 - 05/2014
2Glioblastoma (Glioblastoma Multiforme)
05/2014 - 02/2012
2Glioma (Gliomas)
05/2014 - 02/2012
2Aneuploidy (Aneuploid)
04/2013 - 06/2007
1Brain Neoplasms (Brain Tumor)
01/2020
1Retinoblastoma (Glioblastoma, Retinal)
01/2020
1Rhabdoid Tumor (Rhabdoid Tumors)
01/2015
1Colorectal Neoplasms (Colorectal Cancer)
01/2015
1Breast Neoplasms (Breast Cancer)
01/2015
1Prostatic Neoplasms (Prostate Cancer)
01/2015
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2015
1Triple Negative Breast Neoplasms
09/2014
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
06/2014
1Anemia
06/2014
1Leukopenia
06/2014
1Non-Hodgkin Lymphoma (Lymphosarcoma)
06/2014
1Multiple Myeloma
06/2014
1Neutropenia
06/2014
1Thrombocytopenia (Thrombopenia)
06/2014
1Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
06/2014
1Ovarian Neoplasms (Ovarian Cancer)
05/2014
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2014
1Carcinogenesis
01/2014
1Urinary Bladder Neoplasms (Bladder Cancer)
04/2013
1Papilloma (Papillomatosis)
04/2013
1Carcinoma (Carcinomatosis)
04/2013
1Medulloblastoma
02/2013
1Leukemia
02/2013
1Neurofibromatosis 1 (Neurofibromatosis Type I)
09/2012
1Neurofibroma
09/2012
1Oligodendroglioma
02/2012
1Epilepsy (Aura)
02/2012
1Astrocytoma (Pilocytic Astrocytoma)
02/2012
1Lymphoma (Lymphomas)
12/2011

Drug/Important Bio-Agent (IBA)

14MLN 8237IBA
01/2020 - 12/2011
14Aurora Kinase AIBA
03/2017 - 03/2007
6Aurora KinasesIBA
12/2015 - 02/2011
4MLN8054IBA
02/2011 - 03/2007
3Heme (Haem)IBA
01/2015 - 06/2014
3Pharmaceutical PreparationsIBA
06/2014 - 02/2012
2Paclitaxel (Taxol)FDA LinkGeneric
01/2020 - 09/2014
2RNA (Ribonucleic Acid)IBA
06/2016 - 04/2013
2Biomarkers (Surrogate Marker)IBA
06/2016 - 02/2011
2Biological ProductsIBA
01/2015 - 05/2014
2Proteins (Proteins, Gene)FDA Link
09/2012 - 02/2012
1Cyclin-Dependent Kinase 6IBA
01/2020
1Circulating Tumor DNAIBA
01/2020
1TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA
12/2015
1SurvivinIBA
12/2015
1Death Domain ReceptorsIBA
12/2015
1LigandsIBA
12/2015
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2015
1Drug CombinationsIBA
01/2015
1Docetaxel (Taxotere)FDA Link
09/2014
1Antineoplastic Agents (Antineoplastics)IBA
09/2014
1AgarIBA
05/2014
1Temozolomide (Temodar)FDA LinkGeneric
05/2014
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
04/2013
1VorinostatFDA Link
02/2013
1Small Interfering RNA (siRNA)IBA
09/2012
1Neurofibromin 1 (Neurofibromin)IBA
09/2012
1Messenger RNA (mRNA)IBA
02/2012
1TubulinIBA
12/2011
1DNA (Deoxyribonucleic Acid)IBA
12/2011
1Antimitotic AgentsIBA
02/2011
1Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
10/2008

Therapy/Procedure

7Therapeutics
03/2017 - 02/2011
2Drug Therapy (Chemotherapy)
05/2014 - 09/2012
2Oral Administration
06/2007 - 03/2007
1Immunotherapy
06/2016